Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 2;8(2):e12988.
doi: 10.1002/jgh3.12988. eCollection 2024 Feb.

Efficacy and safety of pantoprazole and itopride in patients with overlap of gastroesophageal reflux disease and dyspepsia: A prospective, open-label, single-arm pilot study

Sundeep Lakhtakia  1 , Aniruddha P Singh  1 , Neeraj Singla  1 , Sana F Memon  2 , Duvvur N Reddy  1
Affiliations

Efficacy and safety of pantoprazole and itopride in patients with overlap of gastroesophageal reflux disease and dyspepsia: A prospective, open-label, single-arm pilot study

Sundeep Lakhtakia et al. JGH Open. .

Abstract

Background and aim: Combining proton pump inhibitors (PPIs) with prokinetics can provide synergistic action in patients with gastroesophageal reflux disease (GERD) and overlapping dyspepsia, but data regarding this is lacking.

Methods: This single-center, prospective study evaluated the efficacy and safety of 6-week treatment with fixed-drug combination (FDC) of pantoprazole (PPI) and itopride (prokinetic) in 50 patients with ≥3 month history of GERD and overlapping dyspepsia refractory to pantoprazole. Efficacy was assessed as reduction in GERD symptom assessment scale (GSAS) distress score for 15 symptoms from baseline to week 6. Adverse events (AEs) were monitored up to week 6.

Results: Although heartburn was the most common symptom at week 6 (26.8%), its frequency significantly decreased from baseline (84.0%; P <0.01). A similar trend was observed for other symptoms: pressure/discomfort inside chest (19.5%), belching (14.6%), regurgitation (12.2%), bloating (9.8%), flatulence (9.8%), early satiety (7.3%), acidic/sour taste in mouth (7.3%), nausea (7.3%), frequent gurgling in stomach/belly (4.9%), and pressure/lump in throat (2.4%). Mean distress scores of all symptoms markedly decreased at week 6. Three AEs (n = 2) of moderate intensity were reported.

Conclusion: The FDC of pantoprazole and itopride showed favorable efficacy and safety in patients with GERD and overlapping dyspepsia refractory to pantoprazole monotherapy. Nevertheless, further studies are warranted.

Keywords: GERD symptom assessment scale distress score; itopride; overlapping dyspepsia; pantoprazole; refractory gastroesophageal reflux disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient disposition. AE, adverse event.
Figure 2
Figure 2
Frequency of GSAS symptoms from baseline to week 6. *P < 0.05 and **P < 0.01 by McNemar test. GERD, gastroesophageal reflux disease; GSAS, GERD symptom assessment scale.
See this image and copyright information in PMC

References

    1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group . The Montreal definition and classification of gastroesophageal reflux disease: a global evidence‐based consensus. Am. J. Gastroenterol. 2006; 101: 1900–1920. - PubMed
    1. Simadibrata M. Dyspepsia and gastroesophageal reflux disease (GERD): Is there any correlation? Acta Med. Indones. 2009; 41: 222–227. - PubMed
    1. Gyawali CP, Kahrilas PJ, Savarino E et al. Modern diagnosis of GERD: the Lyon Consensus. Gut. 2018; 67: 1351–1362. - PMC - PubMed
    1. Stanghellini V. Functional dyspepsia and irritable bowel syndrome: Beyond Rome IV. Dig. Dis. 2017; 35: 14–17. - PubMed
    1. Bhatia SJ, Makharia GK, Abraham P et al. Indian consensus on gastroesophageal reflux disease in adults: a position statement of the Indian Society of Gastroenterology. Indian J. Gastroenterol. 2019; 38: 411–440. - PubMed